All In MedTech

Device Trial Radar · NCT03103282

Post-market Clinical Study to Confirm Safety and Performance of PuraStat® for the Management of Bleeding in Vascular Surgery.

A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of PuraStat® Absorbable Haemostatic Material for the Management of Bleeding In Vascular Surgery.

Last checked: Nov 20, 2026Latest source record: Dec 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

65

Actual

Start

Jun 14, 2017

Primary completion

Jul 5, 2019

Study completion Aug 30, 2019

Sponsor

Lead sponsor
3-D Matrix Europe SASNot on our public-company list
Sponsor type
Industry
First posted
Apr 6, 2017

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

The objective of this post-market clinical follow-up study is to collect medical information on patients implanted with PuraStat®, according to each participating institution's procedures and standards of care.

Conditions

  • Vascular Anastomosis Surgery

Interventions

  • PuraStat®Device

    Synthetic haemostatic material

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Time-To-HaemostasisTime frame: Intraoperatively

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St George'S University Hospitals Nhs Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.